Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matinas BioPharma (MTNB) just unveiled an update.
Matinas BioPharma Holdings, Inc. has struck a deal with institutional investors, selling over 33 million shares and warrants, aiming to raise about $10 million for corporate purposes. The shares and warrants are priced at $0.30 and $0.35 respectively, with the warrants exercisable in six months and expiring after five and a half years. The company has also agreed on a 90-day lock-up period, preventing further stock or securities issuance, and directors and officers are similarly restricted from selling their holdings. The sale is organized by A.G.P./Alliance Global Partners, who will receive a 7% commission and expense reimbursement. This transaction is part of a previously effective registration statement and has been publicly announced, along with the pricing details.
Find detailed analytics on MTNB stock on TipRanks’ Stock Analysis page.

